MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II

Trial Profile

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Microscopic polyangiitis; Wegener's granulomatosis
  • Focus Therapeutic Use
  • Acronyms MAINRITSAN 2
  • Most Recent Events

    • 18 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2016.
    • 16 Nov 2016 Results analysing ANCA-associated vasculitides relapses presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top